Clinical data of patients treated with infliximab
| No | Ocular diagnoses | Systemic diagnoses | Therapy before infliximab | Current therapy | No of infusion(s) | Follow-up (months) | Visual acuity before infliximab | Visual acuity after infliximab | Inflammation before infliximab therapy | Inflammation after infliximab therapy (at last visit) | Status at last follow-up |
| 1 | Sclerouveitis OU, CMO OU, OAG OU | Crohn disease | Sirolimus, CHLOR, CYCLO, MMF | INF, MMF, Sirolimus | 24 | 27 | OD 20/20, OS 20/25 | OD 20/20, OS 20/40 | 1 injection OU | Quiet OU | Responder, unable to reduce concurrent IMT |
| 2 | Scleritis OU | Crohn disease, RA | CHLOR, MMF, AZA, Pred | INF | 15 | 22 | OU 20/15 | OU 20/15 | Quiet OU | Quiet OU | Responder, able to discontinue all IMT |
| 3 | Scleritis OU | RA | AZA, CYCLOP, MTX | Lost to follow-up, MMF at last visit | 12 | 24 | OU 20/20 | OU 20/20 | 1 injection OU | Quiet OU | Responder, control of inflammation with INF but developed lupus-like reaction |
| 4 | Scleritis with PUK OU | Crohn disease, RA | intravenous MP | INF, MTX, Methylprednisolone | 20 | 21 | OD 20/25, OS 20/20 | OU 20/20 | 2 injection OD, 1 injection OS | Quiet OU | Partial responder, required concurrent antimetabolite and steroid therapy |
| 5 | Scleritis OU | Crohn disease | intravenous MP, Pred | INF | 21 | 20 | OU 20/20 | OU 20/20 | 1 injection OU | Quiet OU | Responder, able to discontinue methylprednisolone infusions |
| 6 | Sclerouveitis OU | RA | MTX, Pred | INF, MTX, Pred | 16 | 14 | OU 20/20 | OU 20/20 | 1 injection OU | Quiet OU | Responder, unable to reduce concurrent IMT |
| 7 | Nodular scleritis OU | None | MMF, CYCLO | INF | 13 | 13 | OU 20/20 | OU 20/20 | Quiet OU | Quiet OU | Responder, able to discontinue all IMT |
| 8 | Scleritis OU | None | MMF, CYCLO, MTX | INF | 8 | 6 | OU 20/40 | OD 20/60, OS 20/20 | 2 injection OU, 1 injection OS | Quiet OU | Responder, able to discontinue all IMT |
| 9 | Nodular scleritis OU | None | MTX, CYCLO | None | 24 | 48 | OU 20/20 | OU 20/20 | 2 injection OU, 1 injection OS | Quiet OU | Responder, able to discontinue all IMT (discontinued INF use because of remission) |
| 10 | Scleritis OS | Behçet disease | Pred, Celecoxib, MMF, MTX,intravenous MP, Chlor, Napr | INF, Napr | 7 | 6 | OU 20/40 | OD 20/60, OS 20/20 | 2 injection OD, 1 injection OS | Quiet OU | Responder, able to discontinue all IMT; use of concomitant naproxen required |
AZA, azathioprine; CHLOR, chlorambucil; CMO, cystoid macular oedema; CYCLO, cyclophosphamide; INF, infliximab; intravenous MP, intravenous methylprednisolone; MMF, mycophenolate mofetil; MTX, methotrexate; Napr, naproxen; OAG, open-angle glaucoma; OD, right eye; OS, left eye; OU, both eyes; PUK, peripheral ulcerative keratitis; RA, rheumatoid arthritis.